scholarly journals Evaluation of Copeptin during Pulmonary Exacerbation in Cystic Fibrosis

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
I. Wojsyk-Banaszak ◽  
P. Sobkowiak ◽  
K. Jończyk-Potoczna ◽  
B. Narożna ◽  
W. Langwiński ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cystic Fibrosis ◽  
Clinical Laboratory ◽  
Complete Blood Count ◽  
Biological Fluids ◽  
Stable Condition ◽  
Inverse Correlation ◽  
Life Questionnaire ◽  
Pulmonary Exacerbation

Copeptin was found to be a stable biomarker of inflammation and stress response in cardiac, renal, metabolic, and respiratory conditions such as pneumonia. The aim of this study was to investigate the copeptin levels in biological fluids (serum and sputum supernatant) of cystic fibrosis pediatric patients during pulmonary exacerbation and remission and to investigate the possible influence of copeptin levels on disease severity and quality of life. Copeptin serum concentrations were measured in 28 pediatric cystic fibrosis (CF) patients: 13 in stable condition and 15 during pulmonary exacerbation. In 10 CF patients, copeptin was also measured in the sputum. In all the patients, we assessed complete blood count, BMI, sputum culture, lung function, and chest imaging (with Brasfield score). The severity of symptoms was assessed using the Shwachman-Kulczycki (SK) score, and the quality of life was assessed with the Cystic Fibrosis Quality of Life Questionnaire-Revised (CFQ-R). Copeptin concentrations in serum and sputum supernatant was measured using an ELISA kit. Statistical analysis was done in Statistica v.12. Serum and sputum copeptin levels were higher in CF patients during pulmonary exacerbation than in a stable period, but the differences were not significant (p=0.58 and p=0.13, respectively). Copeptin did not correlate significantly with any clinical, laboratory, or spirometry markers of exacerbation. There was, however, a significant inverse correlation between the serum copeptin level and symptoms severity (r=‐0.77, p=0.008) and radiological changes (r=‐0.5626, p=0.036) during pulmonary exacerbation in pediatric CF patients. Copeptin also inversely correlated with the quality of life domains in CF patients: vitality and eating habits, mostly loss of appetite (p=0.031 and p=0.016, respectively). Copeptin may be useful to identify patients with a higher risk of deterioration to improve their outcomes.

scholarly journals The Effect of Coaching on Physical Activity and Quality of Life in Children and Adolescents with Cystic Fibrosis: A Quality Improvement Pilot Study

2010 ◽  
Author(s):  
Anne Swisher ◽  
Kathryn Moffett
Keyword(s):  
Quality Of Life ◽  
Physical Activity ◽  
Cystic Fibrosis ◽  
Pilot Study ◽  
Children And Adolescents ◽  
Life Questionnaire ◽  
Activity Levels ◽  
Small Pilot Study ◽  
Phone Calls

Purpose: Physical activity is well known to improve or maintain exercise capacity and overall health in patients with cystic fibrosis (CF). However, many patients do not meet recommended guidelines for physical activity. The purpose of this study was to determine if individualized, targeted coaching could improve the levels of physical activity and quality of life in children and adolescents with CF. Subjects: Twelve children with CF, ages 7 to 17, participated in this study.Method: Each participant completed a physical activity questionnaire (PAQ) and a disease-specific quality of life questionnaire (CFQ) at baseline and three months later. The participants were given pedometers and a 10,000 step per day target. Participants also participated in discussions regarding ways to increase physical activity appropriate for their interest, abilities and age. Weekly follow-up phone calls were made to obtain pedometer counts and discuss physical activities performed. Results: Physical activity scores (PAQ) improved in 6 of 12 participants. Quality of life improved in many dimensions of the CFQ, particularly in vitality (3 of 5 improved); emotional (8 of 12 improved) and respiratory (7 of 12 improved). Conclusions: The results of this small pilot study suggest that an individualized coaching approach to physical activity in children and adolescents with CF may improve physical activity levels and improve important aspects of quality of life in some children with CF.

scholarly journals A systematic review of patient-reported outcome measures (PROMs) in cystic fibrosis

BMJ Open ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. e033867
Author(s):  
Irushi Ratnayake ◽  
Susannah Ahern ◽  
Rasa Ruseckaite
Keyword(s):  
Quality Of Life ◽  
Cystic Fibrosis ◽  
Outcome Measures ◽  
Patient Reported Outcome Measures ◽  
Patient Reported Outcome ◽  
Cochrane Library ◽  
Life Questionnaire ◽  
Health Measurement ◽  
Patient Reported

BackgroundTo determine patient-reported outcome measures (PROMs) which may be suitable for incorporation into the Australian Cystic Fibrosis Data Registry (ACFDR) by identifying PROMs administered in adult and paediatric cystic fibrosis (CF) populations in the last decade.MethodsWe searched MEDLINE, EMBASE, Scopus, CINAHL, PsycINFO and Cochrane Library databases for studies published between January 2009 and February 2019 describing the use of PROMs to measure health-related quality of life (HRQoL) in adult and paediatric patients with CF. Validation studies, observational studies and qualitative studies were included. The search was conducted on 13 February 2019. The COnsensus-based Standards for the selection of health Measurement INstruments Risk of Bias Checklist was used to assess the methodological quality of included studies.ResultsTwenty-seven different PROMs were identified. The most commonly used PROMs were designed specifically for CF. Equal numbers of studies were conducted on adult (32%, n=31), paediatric (35%, n=34) and both (27%, n=26) populations. No PROMs were used within a clinical registry setting previously. The two most widely used PROMs, the Cystic Fibrosis Questionnaire—Revised (CFQ-R) and the Cystic Fibrosis Quality of Life Questionnaire (CFQoL), demonstrated good psychometric properties and acceptability in English-speaking populations.DiscussionWe found that although PROMs are widely used in CF, there is a lack of reporting on the efficacy of methods and timepoints of administration. We identified the CFQ-R and CFQoL as the most suitable for incorporation in the ACFDR as they captured significant effects of CF on HRQoL and were reliable and valid in CF populations. These PROMs will be used in a further qualitative study assessing patients’ with CF and clinicians’ perspectives toward the acceptability and feasibility of incorporating a PROM in the ACFDR.PROSPERO registration numberCRD42019126931.

scholarly journals Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 575 ◽  
Author(s):  
Kate Skolnik ◽  
Bradley S. Quon
Keyword(s):  
Quality Of Life ◽  
Cystic Fibrosis ◽  
Significant Proportion ◽  
Pulmonary Exacerbation ◽  
Aggressive Treatment ◽  
Profound Impact ◽  
Recent Advances ◽  
Intravenous Antibiotics ◽  
Pulmonary Exacerbations

Pulmonary exacerbations are common events in cystic fibrosis and have a profound impact on quality of life, morbidity, and mortality. Pulmonary exacerbation outcomes remain poor and a significant proportion of patients fail to recover their baseline lung function despite receiving aggressive treatment with intravenous antibiotics. This focused review provides an update on some of the recent advances that have taken place in our understanding of the epidemiology, pathophysiology, diagnosis, and management of pulmonary exacerbations in cystic fibrosis as well as direction for future study.

scholarly journals Inhaled antibiotics therapy for stable non-cystic fibrosis bronchiectasis: a meta-analysis

2020 ◽  
Vol 14 ◽  
pp. 175346662093686 ◽  
Author(s):  
Meng-Jiao Xu ◽  
Bing Dai
Keyword(s):  
Quality Of Life ◽  
Cystic Fibrosis ◽  
Meta Analysis ◽  
Bacterial Load ◽  
Great Promise ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Life Questionnaire ◽  
Inhaled Antibiotics

Background: The optimum antibiotic therapy for non-cystic fibrosis bronchiectasis (NCFB) has yet to be determined. A meta-analysis was conducted to evaluate the efficacy and safety of inhaled antibiotics in adults with stable NCFB. Methods: PubMed, EMBASE, MEDLINE and the Cochrane Central Register of Controlled Trials were searched through November 2019. Results: A total of 16 randomized controlled trials (RCTs), recruiting 2748 NCFB patients, were finally included. Inhaled antibiotics treatment significantly reduced the sputum bacterial load [standard mean difference (SMD) = –0.74, 95% CI: –1.16–0.32, p < 0.001, I2 = 68.1%], prolonged median time [hazard risk (HR) = 0.73, 95% confidence interval (CI): 0.57–0.93, p < 0.001, I2 = 53.6%] and reduced frequency [incidence rate ratio (IRR) = 0.74, 95% CI 0.63–0.87, p < 0.001, I2 = 20.5%] of exacerbations, with good tolerance. However, it failed to improve Pseudomonas aeruginosa eradication, [forced expiratory volume in 1 s (FEV1)] % predicted, quality of life questionnaire (QoL-B) and St. George’s respiratory questionnaire (SGRQ) scores, and may induce higher risk of P. aeruginosa resistance. Subgroup analysis showed Ciprofloxacin was more effective than other antibiotics in reducing bacterial load (SMD = –1.35, 95% CI: –1.85–0.85, I2 = 63.4%, p = 0.042). Conclusion: Inhaled antibiotics therapy holds great promise for stable NCFB as it is effective in reducing sputum bacterial load and the risk of acute attack, delaying disease progression, and is well tolerated. Although this study brings some constructive ideas in the field of clinical medication, further clinical trials should be carried out, particularly in solving drug-resistance and improving health-related quality of life (HRQoL), which we believe will finally provide benefits for patients suffering from bronchiectasis. The reviews of this paper are available via the supplemental material section.

scholarly journals THE EFFECT OF THE HYPERLEPTINEMIA ON THE QUALITY OF LIFE OF HYPERTENSIVE PATIENTS WITH METABOLIC SYNDROME

2013 ◽  
Vol 19 (5) ◽  
pp. 428-424 ◽  
Author(s):  
I. D. Bespalova ◽  
V. V. Kalyuzhin ◽  
Y. A. Medyantsev ◽  
I. A. Osikhov ◽  
B. Y. Murashev ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Metabolic Syndrome ◽  
Essential Hypertension ◽  
Metabolic Disorders ◽  
Clinical Laboratory ◽  
Inverse Correlation ◽  
Serum Leptin ◽  
Laboratory Markers ◽  
Sf 36

Objective. To study interconnection between hyperleptinemia, the quality of life (QOL) and the severity of metabolic disorders in patients with essential hypertension with metabolic syndrome (MS). Design and methods.We have examined 46 patients with essential hypertension (blood pressure < 180/110 mm Hg), accompanied by MS. Along with complete clinical, laboratory and instrumental examination, customary in a specialized cardiologic clinic, the QOL research was carried out using MOS SF-36questionnaire. Besides, the concentration of leptin in blood serum was determined.Results and conclusions. Patients with essential hypertension with hyperleptinemia show higher intensity of clinical and laboratory markers of MS, higher activity of the systemic inlammatory response and increased QOL. A statistically signiicant inverse correlation between serum leptin level and QOL scales (SF-36) was detected.

scholarly journals Validation of the Danish version of the revised cystic fibrosis quality of life questionnaire in adolescents and adults (CFQ-R14+)

2008 ◽  
Vol 7 (6) ◽  
pp. 531-536 ◽  
Author(s):  
Vibeke Bregnballe ◽  
Mikael Thastum ◽  
Liat Damsbo Lund ◽  
Christine Rønne Hansen ◽  
Tacjana Preissler ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cystic Fibrosis ◽  
Life Questionnaire ◽  
Quality Of Life Questionnaire ◽  
Danish Version ◽  
Adolescents And Adults
Sign in / Sign up

Export Citation Format

Share Document